4 results
(Protocol Am2 dd. 20-Feb-2014, p17/93)The primary objectives of this study are:- To evaluate the safety of sofosbuvir (SOF) 200 mg or 400 mg + ribavirin (RBV) for 24 weeks as assessed by review of the accumulated safety data in each treatment arm-…
To assess the efficacy of blood pressure lowering and the safety of increasing doses of perindopril and amlodipine combination and to compare them to another validated antihypertensive strategy using valsartan and valsartan combined to amlodipine.
To assess the bioequivalence of two marketed formulations of ribavirin (ribavirin solution and capsules).
To compare the efficacy of VRd followed by cilta-cel therapy versus VRd followed by Rd therapy in terms of progression free survival (PFS)